PAI
SNDX icon

Palo Alto Investors’s Syndax Pharmaceuticals SNDX Stock Holding History

Palo Alto Investors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.2M Buy
864,986
+70,479
+9% +$1.53M 3.09% 12
2025
Q4 		$16.7M Buy
794,507
+139,577
+21% +$2.44M 2.32% 13
2025
Q3 		$10.1M Buy
654,930
+210,563
+47% +$2.76M 1.86% 18
2025
Q2 		$4.16M Hold
444,367
– – 0.89% 20
2025
Q1 		$5.46M Buy
444,367
+39,174
+10% +$553K 1.04% 20
2024
Q4 		$5.36M Hold
405,193
– – 0.83% 20
2024
Q3 		$7.8M Hold
405,193
– – 1.01% 20
2024
Q2 		$8.32M Hold
405,193
– – 0.96% 19
2024
Q1 		$9.64M Sell
405,193
-67,407
-14% -$1.5M 1.09% 20
2023
Q4 		$10.2M Hold
472,600
– – 0.92% 19
2023
Q3 		$6.86M Sell
472,600
-140,000
-23% -$2.65M 0.65% 19
2023
Q2 		$12.8M Hold
612,600
– – 1.04% 15
2023
Q1 		$12.9M Hold
612,600
– – 1.07% 15
2022
Q4 		$15.6M Hold
612,600
– – 1.33% 14
2022
Q3 		$14.7M Hold
612,600
– – 1.16% 15
2022
Q2 		$11.8M Hold
612,600
– – 1.03% 17
2022
Q1 		$10.6M Buy
612,600
+13,700
+2% +$231K 0.82% 20
2021
Q4 		$13.1M Buy
598,900
+154,000
+35% +$2.85M 0.84% 21
2021
Q3 		$8.5M Buy
444,900
+43,800
+11% +$730K 0.51% 25
2021
Q2 		$6.89M Buy
401,100
+136,900
+52% +$2.51M 0.38% 25
2021
Q1 		$5.91M Hold
264,200
– – 0.34% 26
2020
Q4 		$5.88M Buy
264,200
+65,800
+33% +$1.36M 0.31% 24
2020
Q3 		$2.93M Buy
198,400
+70,700
+55% +$1.08M 0.16% 27
2020
Q2 		$1.89M Buy
127,700
+61,600
+93% +$938K 0.11% 29
2020
Q1 		$725K Buy
+66,100
New +$620K 0.06% 29

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Palo Alto Investors's SNDX Position: Q1 2026 in Review

Palo Alto Investors increased its Syndax Pharmaceuticals (SNDX) stake by 8.9% in Q1 2026, buying an estimated $1.53M and bringing the position to 864,986 shares worth $20.2M. The position accounts for 3.09% of the portfolio, ranked #12.

Palo Alto Investors first reported a position in SNDX in Q1 2020 and has held it in 25 quarters since. 247 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Palo Alto Investors held 864,986 shares of Syndax Pharmaceuticals worth $20.2M as of Q1 2026.
  • Palo Alto Investors bought 70,479 Syndax Pharmaceuticals shares in Q1 2026, an estimated $1.53M.
  • Syndax Pharmaceuticals made up 3.09% of Palo Alto Investors's portfolio in Q1 2026, its #12 holding.
  • Palo Alto Investors first reported a position in Syndax Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
  • 247 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.